Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis.
J Antimicrob Chemother
; 79(4): 712-721, 2024 Apr 02.
Article
de En
| MEDLINE
| ID: mdl-38323372
ABSTRACT
BACKGROUND:
The indications of daptomycin have been extended to off-label indications including prosthesis-related infection, and bone and joint infection (BJI). However, efficacy and safety have not been thoroughly demonstrated compared with the standard of care. This systematic review and meta-analysis aimed to compare the treatment effect of daptomycin and glycopeptides for complicated infections. MATERIALS ANDMETHODS:
MEDLINE, Embase and Web of Science were searched for randomized controlled trials (RCTs) comparing daptomycin and standard of care for Gram-positive infections, published until 30 June 2021. The primary outcome was defined as all-cause mortality. Secondary outcomes were clinical and microbiological success. The main safety outcome was any severe adverse event (SAE) (grade â≥3).RESULTS:
Overall, eight RCTs were included in the meta-analysis, totalling 1095 patients. Six (75%) were in complicated skin and soft-structure infections, one (12.5%) in bacteraemia and one (12.5%) in a BJI setting. Six RCTs used vancomycin as a comparator and two used either vancomycin or teicoplanin. All-cause mortality and clinical cure were not different between groups. The microbiological cure rate was superior in patients who received daptomycin [risk ratio (RR)â=â1.17 (95% CI 1.01-1.35)]. The risk of SAEs [RRâ=â0.57 (95% CI 0.36-0.90)] was lower in the daptomycin arm.CONCLUSIONS:
While daptomycin is associated with a significantly lower risk of SAEs and a better microbiological eradication, substantial uncertainty remains about the best treatment strategy in the absence of good-quality evidence, especially in bacteraemia and endocarditis where further RCTs should be conducted.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Glycopeptides
/
Infections bactériennes à Gram positif
/
Daptomycine
/
Antibactériens
Type d'étude:
Clinical_trials
/
Systematic_reviews
Limites:
Humans
Langue:
En
Journal:
J Antimicrob Chemother
/
J. antimicrob. chemother
/
Journal of antimicrobial chemotherapy
Année:
2024
Type de document:
Article
Pays d'affiliation:
France
Pays de publication:
Royaume-Uni